| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/30/2007 | US7169384 Gene for which is located on the short arm of human chromosome 1; gene is directly implicated in colon, kidney and breast cancers |
| 01/30/2007 | US7169383 Attaching substances to micro-organisms |
| 01/30/2007 | US7168847 Device for mixing and/or injecting cements |
| 01/30/2007 | CA2302017C Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
| 01/30/2007 | CA2284859C Nucleic acid molecule for a human skeletal muscle-specific receptor |
| 01/30/2007 | CA2247328C Neuropeptides originating in scorpion |
| 01/30/2007 | CA2210751C Anti-cd6 monoclonal antibodies and their uses |
| 01/30/2007 | CA2185794C Agent for relieving side effects caused by immunosuppressants |
| 01/30/2007 | CA2167693C Melanoma-inhibiting protein |
| 01/30/2007 | CA2138991C Treatment for sensitive teeth |
| 01/30/2007 | CA2107537C Inhibition of tumor cell growth by administration of b7-transfected cells |
| 01/30/2007 | CA1341520C Peptides capable of binding hiv (human immunodeficiency virus) antibodies, their use in diagnosis hiv infections, or for aids vaccination |
| 01/25/2007 | WO2007012066A2 TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF |
| 01/25/2007 | WO2007012064A2 Prevention and treatment of hearing disorders |
| 01/25/2007 | WO2007012061A2 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 01/25/2007 | WO2007012006A1 Methods and compositions for emergency contraception using endothelin receptor antagonists |
| 01/25/2007 | WO2007011958A2 Intraoral dosage forms of glucagon |
| 01/25/2007 | WO2007011875A2 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| 01/25/2007 | WO2007011859A2 Identification of a novel bitter taste receptor t2r76 that specifically responds to brucine and prop bitter ligands |
| 01/25/2007 | WO2007011827A2 G1 cytostatic agents enhancing antiviral activity of viral-envelope targeting drugs and antibodies |
| 01/25/2007 | WO2007011777A2 Small animal model for hcv replication |
| 01/25/2007 | WO2007011773A2 Reduction in myocardial infarction size |
| 01/25/2007 | WO2007011757A1 Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| 01/25/2007 | WO2007011670A2 Heterodimeric four helix bundle cytokines |
| 01/25/2007 | WO2007011610A2 Protein formulation for promoting hard tissue formation |
| 01/25/2007 | WO2007011434A2 Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| 01/25/2007 | WO2007011340A1 Methods for treating prostate cancer |
| 01/25/2007 | WO2007011265A1 Method for blocking noggin2 target specific activities |
| 01/25/2007 | WO2007010999A1 Animal in which lipid metabolism and sugar metabolism are modified by krap gene mutation, modification method and modifying agent |
| 01/25/2007 | WO2007010989A1 Neuronal differentiation-inducing peptide and use thereof |
| 01/25/2007 | WO2007010892A1 Novel phospholipid processing agent |
| 01/25/2007 | WO2007010853A1 Method for control of electroporation apparatus |
| 01/25/2007 | WO2007010692A1 Pharmaceutical composition for treatment of inflammatory bowel disease which targets at hvem and btla, and therapeutic method |
| 01/25/2007 | WO2007010628A1 Prophylactic/therapeutic agent for cancer |
| 01/25/2007 | WO2007010394A2 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| 01/25/2007 | WO2007010283A1 Serine beta-lactamase-like / d-ala carboxypeptidase-like protein |
| 01/25/2007 | WO2007010258A2 Polymorphism in cysteine dioxygenase |
| 01/25/2007 | WO2007010216A1 Lycopene formulations for the treatment of atherosclerotic conditions |
| 01/25/2007 | WO2007010128A1 Target vector with activable imaging function |
| 01/25/2007 | WO2007009946A2 Process for the manufacture of eptifibatide |
| 01/25/2007 | WO2007009404A1 Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system |
| 01/25/2007 | WO2007009383A1 A rectum suppository of protein and its preparation method and the use |
| 01/25/2007 | WO2007009382A1 Use of rhgm-csf for the manufacturing of an external medicament for the treatment of cervicitis and/or cervical erosion |
| 01/25/2007 | WO2007009359A1 Thymosin beta 4 derivatives and use thereof |
| 01/25/2007 | WO2007009317A2 Peptide drug for inhibiting solid tumour and cancer cell of leukaemia |
| 01/25/2007 | WO2007009265A1 NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS |
| 01/25/2007 | WO2007009208A1 Poly(ethylene glocol) modified human gm-csf with increased biological activity |
| 01/25/2007 | WO2007009194A1 Sra binding protein |
| 01/25/2007 | WO2007009166A1 Modulation of granulosa cell apoptosis |
| 01/25/2007 | WO2006130022A8 Modulation of ovulation by agonists and antagonists of bmprii |
| 01/25/2007 | WO2006128266A3 Pharmaceutical compositions of the peptide angiotensin-(1 -7) [ang-(i -7)] and its analogues, agonists and antagonists, for use in controlling the functions of the reproductive system |
| 01/25/2007 | WO2006119061A3 Hcv ns3 protease inhibitors |
| 01/25/2007 | WO2006114439A3 Novel nutraceutical compositions |
| 01/25/2007 | WO2006105219A3 T cell therapy for the treatment of cachexia and chronic diseases |
| 01/25/2007 | WO2006097537A3 Acylated glp-1 compounds |
| 01/25/2007 | WO2006096285A3 Compositions and methods for treating or preventing flaviviridae infections |
| 01/25/2007 | WO2006085226A3 Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by insulin-like growth factor binding protein-3 (igfbp-3) |
| 01/25/2007 | WO2006083949A3 Sepsis prevention through adenosine receptor modulation |
| 01/25/2007 | WO2006078588A3 Improved methods for treating headache |
| 01/25/2007 | WO2006078414A3 METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE |
| 01/25/2007 | WO2006076014A3 Interferon-alpha constructs for use in the treatment of sars |
| 01/25/2007 | WO2006073890A3 Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis |
| 01/25/2007 | WO2006071200A3 Chinese hamster apoptosis-related genes |
| 01/25/2007 | WO2006046072A3 VWFA AND/OR ANT_IG DOMAIN CONTAINING PROTEINS |
| 01/25/2007 | WO2006031607A3 A method of treating cancer |
| 01/25/2007 | WO2006027116A3 P277 peptide formulations or variants thereof having optimised stability |
| 01/25/2007 | WO2005123128A3 Methods for treating conditions associated with masp-2 dependent complement activation |
| 01/25/2007 | WO2005118527A3 Fluorous capping reagents, and methods for peptide purification |
| 01/25/2007 | WO2005115435A3 Methods and compositions for control of fetal growth via modulation of relaxin |
| 01/25/2007 | WO2005097998A3 Il-18 specific polypeptides and therapeutic uses thereof |
| 01/25/2007 | WO2005086773A3 A method for delivering therapeutic proteins to the intradermal compartment |
| 01/25/2007 | WO2005065079A3 Medical implants and fibrosis-inducing agents |
| 01/25/2007 | WO2004063342A3 Cellular delivery and activation polypeptide-nucleic acid complexes |
| 01/25/2007 | US20070021593 for use in the treatment of inflammation and ischemia-reperfusion injury |
| 01/25/2007 | US20070021590 Secreted protein family |
| 01/25/2007 | US20070021589 Obesity-related genes |
| 01/25/2007 | US20070021464 Methods and compositions for inhibition of angiogenesis with EM-12 Derivatives |
| 01/25/2007 | US20070021375 Genetic modification of targeted regions of the cardiac conduction system |
| 01/25/2007 | US20070021367 Modulation of SOCS-3 expression |
| 01/25/2007 | US20070021361 Methods and materials for modulating trpm2 |
| 01/25/2007 | US20070021354 Viricides; immunomoderator; mixture with other Aids drugs |
| 01/25/2007 | US20070021353 Alpha ketoamide compounds as cysteine protease inhibitors |
| 01/25/2007 | US20070021352 Prevention and treatment of hearing disorders |
| 01/25/2007 | US20070021351 Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| 01/25/2007 | US20070021350 Conjugates useful in the treatment of prostate cancer |
| 01/25/2007 | US20070021349 Orthogonally protected bifunctional amino acid |
| 01/25/2007 | US20070021348 Novel treatment |
| 01/25/2007 | US20070021347 Antitumor peptide; risk of adverse immune reactions such as anaphylactic shock is greatly diminished |
| 01/25/2007 | US20070021346 N-terminally modified GLP-1 receptor modulators |
| 01/25/2007 | US20070021345 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| 01/25/2007 | US20070021344 Stabilized teriparatide solutions |
| 01/25/2007 | US20070021343 preparing a sealed vial or sealed cartridge for storage stability, resist to oxidation and chemical; including BUFFER AND A POLYOL; MANNITOL, BUFFER OF AN ACETATE OR TARTRATE, M-CRESOL OR BENZYL ALCOHOL PRESERVATIVE; parathyroid hormone for treating osteoporosis |
| 01/25/2007 | US20070021342 Wound Healing |
| 01/25/2007 | US20070021341 Treatment of autoimmune conditions with Copolymer 1 and related Copolymers |
| 01/25/2007 | US20070021340 Use of blood coagulation factor XIII for treating hemophilia A |
| 01/25/2007 | US20070021339 Glucagon-like peptide-1 (GLP-1); for treatment of diabetes, obesity, excessive appetite, insufficient satiety, and metabolic disorders; for converting liver stem/progenitor cells into functional pancreatic cells |
| 01/25/2007 | US20070021338 Stabilised compositions of Factor VII |
| 01/25/2007 | US20070021337 Novel agent for inducing apoptosis comprising Msx1 or a gene encoding the same as an active ingredient |
| 01/25/2007 | US20070021336 Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis |
| 01/25/2007 | US20070021335 Agent for improving mental disorders |